Commenting on the results, Vas Narasimhan, CEO of Novartis, said: “We progressed our breakthrough medicines pipeline including our leading advanced therapy platforms in cell and gene and continued our strong operational performance.”
Download the media release
Interim financial report (PDF 0.7 MB)